267 related articles for article (PubMed ID: 21273213)
1. Inhibition of vascular endothelial growth factor (VEGF) is sufficient to completely restore barrier malfunction induced by growth factors in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2011 Aug; 95(8):1151-6. PubMed ID: 21273213
[TBL] [Abstract][Full Text] [Related]
2. VEGF but not PlGF disturbs the barrier of retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Exp Eye Res; 2013 Oct; 115():162-71. PubMed ID: 23891860
[TBL] [Abstract][Full Text] [Related]
3. Capacity of aflibercept to counteract VEGF-stimulated abnormal behavior of retinal microvascular endothelial cells.
Deissler HL; Lang GK; Lang GE
Exp Eye Res; 2014 May; 122():20-31. PubMed ID: 24631334
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of protein kinase C is not sufficient to prevent or reverse effects of VEGF165 on claudin-1 and permeability in microvascular retinal endothelial cells.
Deissler HL; Deissler H; Lang GE
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):535-42. PubMed ID: 19643968
[TBL] [Abstract][Full Text] [Related]
5. Ranibizumab efficiently blocks migration but not proliferation induced by growth factor combinations including VEGF in retinal endothelial cells.
Deissler HL; Deissler H; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2013 Oct; 251(10):2345-53. PubMed ID: 23760670
[TBL] [Abstract][Full Text] [Related]
6. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells.
Deissler H; Deissler H; Lang S; Lang GE
Br J Ophthalmol; 2008 Jun; 92(6):839-43. PubMed ID: 18511543
[TBL] [Abstract][Full Text] [Related]
7. Binding of VEGF-A is sufficient to abrogate the disturbing effects of VEGF-B together with VEGF-A on retinal endothelial cells.
Deissler HL; Lang GK; Lang GE
Graefes Arch Clin Exp Ophthalmol; 2015 Jun; 253(6):885-94. PubMed ID: 25663437
[TBL] [Abstract][Full Text] [Related]
8. Actions of bevacizumab and ranibizumab on microvascular retinal endothelial cells: similarities and differences.
Deissler HL; Deissler H; Lang GE
Br J Ophthalmol; 2012 Jul; 96(7):1023-8. PubMed ID: 22539748
[TBL] [Abstract][Full Text] [Related]
9. Blocking of VEGF-A is not sufficient to completely revert its long-term effects on the barrier formed by retinal endothelial cells.
Deissler HL; Rehak M; Busch C; Wolf A
Exp Eye Res; 2022 Mar; 216():108945. PubMed ID: 35038456
[TBL] [Abstract][Full Text] [Related]
10. Effects of VEGFR-1, VEGFR-2, and IGF-IR hammerhead ribozymes on glucose-mediated tight junction expression in cultured human retinal endothelial cells.
Spoerri PE; Afzal A; Li Calzi S; Shaw LC; Cai J; Pan H; Boulton M; Grant MB
Mol Vis; 2006 Jan; 12():32-42. PubMed ID: 16446700
[TBL] [Abstract][Full Text] [Related]
11. Angiopoietin modulation of vascular endothelial growth factor: Effects on retinal endothelial cell permeability.
Peters S; Cree IA; Alexander R; Turowski P; Ockrim Z; Patel J; Boyd SR; Joussen AM; Ziemssen F; Hykin PG; Moss SE
Cytokine; 2007 Nov; 40(2):144-50. PubMed ID: 17959386
[TBL] [Abstract][Full Text] [Related]
12. Endostatin modulates VEGF-mediated barrier dysfunction in the retinal microvascular endothelium.
Brankin B; Campbell M; Canning P; Gardiner TA; Stitt AW
Exp Eye Res; 2005 Jul; 81(1):22-31. PubMed ID: 15978251
[TBL] [Abstract][Full Text] [Related]
13. VEGF activation of protein kinase C stimulates occludin phosphorylation and contributes to endothelial permeability.
Harhaj NS; Felinski EA; Wolpert EB; Sundstrom JM; Gardner TW; Antonetti DA
Invest Ophthalmol Vis Sci; 2006 Nov; 47(11):5106-15. PubMed ID: 17065532
[TBL] [Abstract][Full Text] [Related]
14. Modulation of VEGF-induced retinal vascular permeability by peroxisome proliferator-activated receptor-β/δ.
Suarez S; McCollum GW; Bretz CA; Yang R; Capozzi ME; Penn JS
Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):8232-40. PubMed ID: 25406289
[TBL] [Abstract][Full Text] [Related]
15. Altered expression of genes related to blood-retina barrier disruption in streptozotocin-induced diabetes.
Klaassen I; Hughes JM; Vogels IM; Schalkwijk CG; Van Noorden CJ; Schlingemann RO
Exp Eye Res; 2009 Jun; 89(1):4-15. PubMed ID: 19284967
[TBL] [Abstract][Full Text] [Related]
16. Involvement of MAPKs in endostatin-mediated regulation of blood-retinal barrier function.
Campbell M; Collery R; McEvoy A; Gardiner TA; Stitt AW; Brankin B
Curr Eye Res; 2006 Dec; 31(12):1033-45. PubMed ID: 17169842
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit VEGF- and basic fibroblast growth factor-induced angiogenesis in vivo and in vitro.
Tille JC; Wood J; Mandriota SJ; Schnell C; Ferrari S; Mestan J; Zhu Z; Witte L; Pepper MS
J Pharmacol Exp Ther; 2001 Dec; 299(3):1073-85. PubMed ID: 11714897
[TBL] [Abstract][Full Text] [Related]
18. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo.
Lowe J; Araujo J; Yang J; Reich M; Oldendorp A; Shiu V; Quarmby V; Lowman H; Lien S; Gaudreault J; Maia M
Exp Eye Res; 2007 Oct; 85(4):425-30. PubMed ID: 17714704
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
20. [In vitro studies on the mechanism of action of VEGF and its inhibitors].
Deissler HL; Lang GE
Klin Monbl Augenheilkd; 2008 Jul; 225(7):623-8. PubMed ID: 18642204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
